^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    prednisone

    Company:
    Generic mfg.
    Drug class:
    Steroid receptor agonist
    Related drugs:
    18d
    Orelabrutinib Combined With Induction Therapy Followed by Sequential Monotherapy Maintenance in MCD Subtype Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
    P2, N=66, Not yet recruiting, Ou Bai, MD/PHD
    New P2 trial
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Inokai (orelabrutinib) • Polivy (polatuzumab vedotin-piiq) • thiotepa • Anruixi (zuberitamab)
    18d
    Immune checkpoint inhibitor-induced myasthenia gravis and myocarditis: a fatal immune-related adverse event. (PubMed, Immunol Res)
    Given the refractory nature of his disease course, he was subsequently treated with a repeat dose of IVIG and prednisone, then transferred to an outside facility for plasma exchange. This case highlights the rare but potentially fatal concurrent occurrence of immune-related myasthenia gravis and myocarditis as irAEs in a patient receiving durvalumab for cholangiocarcinoma. While checkpoint inhibitors have revolutionized outcomes across many solid tumor malignancies, this case underscores the diagnostic and management challenges posed by severe, refractory irAEs, and the importance of early recognition and aggressive treatment in this patient population.
    Journal • Adverse events • Checkpoint inhibition
    |
    PD-1 (Programmed cell death 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    Imfinzi (durvalumab) • prednisone
    19d
    A Study of BEBT-908 in Combination With Chemotherapy in Patients With Previously Untreated Peripheral T-Cell Lymphoma (PTCL) (clinicaltrials.gov)
    P2, N=120, Not yet recruiting, BeBetter Med Inc
    New P2 trial
    |
    doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone
    19d
    GLORIFY: Evaluation of Treatment by Glofitamab in Combination With Rituximab or Obinutuzumab Plus CHOP in Patients With RIchter Syndrome (clinicaltrials.gov)
    P2, N=40, Recruiting, French Innovative Leukemia Organisation | Trial completion date: Mar 2027 --> Sep 2029 | Trial primary completion date: Mar 2026 --> Mar 2028
    Trial completion date • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • Gazyva (obinutuzumab) • cyclophosphamide • vincristine • prednisone • Columvi (glofitamab-gxbm)
    20d
    From Unicentric Castleman Disease to Lymphoma: A Rare Case Highlighting a Diagnostic and Therapeutic Challenge. (PubMed, Cureus)
    Due to the diagnostic complexity, he was treated as having a non-Hodgkin lymphoma-like entity with R-CHOP chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) Although UCD is typically considered curable with surgical resection, this case demonstrates that, in rare cases, it can progress to lymphoma, specifically NLPHL. This case illustrates that even localized forms of UCD may be associated with subsequent lymphoid malignancy, emphasizing the importance of continuous clinical surveillance and a multidisciplinary approach to management. Histopathological reassessment of new lesions is crucial, and clinicians should consider the possibility of malignant transformation in patients with a history of UCD to ensure accurate diagnosis and timely treatment.
    Journal
    |
    CD20 (Membrane Spanning 4-Domains A1) • BCL6 (B-cell CLL/lymphoma 6)
    |
    CD20 positive
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone
    24d
    PROSPECT: Study of the Feasibility and Efficacy of PrednisonE for Non-specifiC pleuriTis (clinicaltrials.gov)
    P1, N=40, Recruiting, Icahn School of Medicine at Mount Sinai | Trial completion date: Nov 2026 --> Jun 2027 | Trial primary completion date: Nov 2026 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    prednisone
    24d
    Pharmacokinetics, safety, and efficacy of fuzuloparib in combination with abiraterone acetate and prednisone in patients with metastatic castration-resistant prostate cancer: a phase 1 dose escalation and expansion study. (PubMed, BMC Cancer)
    Fuzuloparib plus AA-P had an acceptable safety profile and showed promising efficacy among mCRPC patients.
    P1 data • PK/PD data • Journal • BRCA Biomarker • PARP Biomarker
    |
    HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    abiraterone acetate • prednisone • AiRuiYi (fluzoparib)
    24d
    A Drug-Drug Interaction Study of Itraconazole and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-017) (clinicaltrials.gov)
    P1, N=14, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed
    Trial completion
    |
    prednisone • itraconazole • opevesostat (MK-5684)
    25d
    Case Report: Successful conversion surgery following chemo-antiangiogenic therapy in a lung adenocarcinoma patient with active rheumatoid arthritis and rare EGFR mutation after immunotherapy-triggered flare. (PubMed, Front Oncol)
    Initial therapy with 'pemetrexed + carboplatin + tislelizumab' was administered...The RA flare was managed with methylprednisolone 1 mg/kg/day followed by a slow prednisone taper and sulfasalazine. Treatment was switched to 'pemetrexed + carboplatin + bevacizumab'...It may create a potential opportunity for conversion surgery in well-responding patients, enabling long-term disease control. This case underscores the critical importance of highly individualized, multidisciplinary treatment decision-making.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53)
    |
    PD-L1 expression • TP53 mutation • EGFR mutation • PD-L1 overexpression
    |
    Avastin (bevacizumab) • carboplatin • Tevimbra (tislelizumab-jsgr) • pemetrexed • prednisone
    25d
    M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501) (clinicaltrials.gov)
    P1, N=60, Active, not recruiting, EMD Serono Research & Development Institute, Inc. | N=141 --> 60
    Enrollment change
    |
    abiraterone acetate • prednisone • tuvusertib (M1774) • M9466 • prednisolone
    25d
    GASPING: Giving Asthmatics Intramuscular Steroids for Preventing Return to the Emergency Department (clinicaltrials.gov)
    P4, N=182, Not yet recruiting, Montefiore Medical Center | Trial completion date: Sep 2026 --> Dec 2026 | Initiation date: Apr 2026 --> Jul 2026 | Trial primary completion date: Sep 2026 --> Dec 2026
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    prednisone • dexamethasone
    26d
    Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) (clinicaltrials.gov)
    P1/2, N=1200, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Keytruda (pembrolizumab) • Lynparza (olaparib) • carboplatin • docetaxel • Lenvima (lenvatinib) • enzalutamide • abiraterone acetate • etoposide IV • prednisone • dexamethasone • Welireg (belzutifan) • vibostolimab/pembrolizumab (MK-7684A)